


Product Information



BAY 41-8543

Catalog No. 10011131

CAS Registry No.: 256498-66-5
Formal Name: 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6-pyrimidinediamine
MF: C₂₁H₂₁FN₈O
FW: 420.4
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid



Laboratory Procedures

For long term storage, we suggest that BAY-41-8543 be stored as supplied at -20°C. It should be stable for at least two years. BAY-41-8543 is supplied as a crystalline solid. A stock solution may be made by dissolving the BAY-41-8543 in the solvent of choice. BAY 41-8543 is soluble in dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of BAY-41-8543 in this solvent is approximately 3 mg/ml.

BAY-41-8543 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BAY-41-8543 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BAY-41-8543 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Soluble guanylate cyclase (sGC) is the primary cellular receptor for nitric oxide (NO). NO binds and activates a heme group in sGC, initiating the conversion of GTP to the second messenger cyclic GMP (cGMP). BAY-41-8543 is a heme-dependent stimulator of sGC, increasing the activity of recombinant sGC dose-dependently, from 0.1 nM to 100 μM, up to 92-fold.¹ Surprisingly, NO donors synergize with BAY-41-8543 in stimulating recombinant sGC.¹ BAY-41-8543 relaxes vessels and inhibits platelet aggregation *in vitro* at nM concentrations.¹ *In vivo*, BAY-41-8543 decreases blood pressure dose-dependently, prolongs bleeding time, and reduces thrombosis.² Inhalation of microparticles containing BAY-41-8543 increases pulmonary vasodilation without changing mean arterial pressure, suggesting that agonists of sGC may be efficacious in treating pulmonary hypertension.³

References

1. Stasch, J.-P., Alonso-Alija, C., Apeler, H., *et al.* Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: *in vitro* studies. *Br. J. Pharmacol.* **135**, 333-343 (2002).
2. Stasch, J.-P., Dembowsky, K., Perzborn, E., *et al.* Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: *in vivo* studies. *Br. J. Pharmacol.* **135**, 344-355 (2002).
3. Evgenov, O.V., Kohane, D.S., Bloch, K.D., *et al.* Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. *Am J Respir Crit Care Med* **176**, 1138-1145 (2007).

Related Products

ODQ - Cat. No. 81410 • YC-1 - Cat. No. 81560 • Guanylate Cyclase α subunit (soluble) Polyclonal Antibody - Cat. No. 160895 • Guanylate Cyclase β1 subunit (soluble) Polyclonal Antibody - Cat. No. 160897

Cayman Chemical

Mailing address
1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone
(800) 364-9897
(734) 971-3335

Fax
(734) 971-3640

E-Mail
custserv@caymanchem.com

Web
www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery.**

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees. Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy** located on our website and in our catalog.

Copyright Cayman Chemical Company, 01/06/2010